2022 年半年度报告 公司代码：600161 公司简称：天坛生物 北京天坛生物制品股份有限公司 2022 年半年度报告 1 / 147 2022 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、未出席董事情况 未出席董事职务 未出席董事姓名 未出席董事的原因说明 被委托人姓名 董事长 杨晓明 因公务 杨汇川 三、本半年度报告未经审计。 四、公司负责人付道兴、主管会计工作负责人张翼及会计机构负责人（会计主管人员）徐颖声明： 保证半年度报告中财务报告的真实、准确、完整。 五、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、是否存在被控股股东及其关联方非经营性占用资金情况 否 八、是否存在违反规定决策程序对外提供担保的情况？ 否 九、是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 ...

Group 1: Event Announcement - Beijing Tiantan Biological Products Co., Ltd. will participate in the "2021 Beijing Listed Companies Investor Collective Reception Day" on September 23, 2021, from 15:00 to 17:00 [1] - The event will be conducted online, allowing investors to join via the Shanghai Stock Exchange Roadshow Center website or its WeChat account [1] Group 2: Communication Details - Company executives, including General Manager Fu Daoxing, CFO Zhang Yi, and Secretary of the Board Ci Xiang, will engage with investors regarding governance, development strategy, operational status, and sustainability [2] - Investors are encouraged to submit questions via email by September 16, 2021, to enhance communication efficiency [2]

2021 年半年度报告 公司代码：600161 公司简称：天坛生物 北京天坛生物制品股份有限公司 2021 年半年度报告 1 / 174 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人付道兴、主管会计工作负责人张翼及会计机构负责人（会计主管人员）朱振海声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 详见"第三节经管理层讨论与分析""五、其他披露事项 ...

2020 年年度报告 公司代码：600161 公司简称：天坛生物 北京天坛生物制品股份有限公司 2020 年年度报告 1 / 224 2020 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人付道兴、主管会计工作负责人张翼及会计机构负责人（会计主管人员）朱振海声 明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 考虑股东利益和公司发展需要，公司拟以2021年4月增发新股后总股本1,373,174,615股为基 数，向全体股东每10股派发现金股利1元(含税)，分红总金额137,317,461.50元（含税）。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经 ...

[Important Notice](index=3&type=section&id=Item%20I.%20Important%20Notice) The board, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of this quarterly report - The company's board of directors, supervisory board, and all senior management guarantee the truthfulness, accuracy, and completeness of this quarterly report, free from false records, misleading statements, or major omissions[4](index=4&type=chunk) - This company's third-quarter report is unaudited[4](index=4&type=chunk) [Company Overview](index=3&type=section&id=Item%20II.%20Company%20Overview) Provides an overview of the company's fundamental information, including key financial data and shareholder structure [Key Financial Data](index=3&type=section&id=2.1%20Key%20Financial%20Data) In the first three quarters of 2020, the company's core financial indicators showed steady growth, with total assets, operating revenue, and net profit attributable to shareholders increasing 2020 First Three Quarters Key Financial Data | Indicator | Year-to-Date (Jan-Sep) | Prior Year-to-Date (Jan-Sep) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 2,635,796,380.87 Yuan | 2,519,395,695.33 Yuan | 4.62% | | Net Profit Attributable to Shareholders | 496,845,783.65 Yuan | 466,879,051.84 Yuan | 6.42% | | Net Cash Flow from Operating Activities | 809,390,647.79 Yuan | 697,313,641.83 Yuan | 16.07% | | Basic Earnings Per Share (Yuan/share) | 0.40 | 0.37 | 6.42% | | Weighted Average Return on Net Assets | 11.91% | 13.02% | Decrease of 1.11 percentage points | - Total assets at the end of the reporting period were **7.608 billion Yuan**, an increase of **20.49%** from the end of the previous year[5](index=5&type=chunk) - Non-recurring gains and losses for the year-to-date totaled **13,323,789.36 Yuan**, primarily from government subsidies[7](index=7&type=chunk)[9](index=9&type=chunk) [Shareholder Information](index=6&type=section&id=2.2%20Total%20Number%20of%20Shareholders%2C%20Top%20Ten%20Shareholders%2C%20and%20Top%20Ten%20Circulating%20Shareholders%20(or%20Unrestricted%20Shareholders)%20as%20of%20the%20End%20of%20the%20Reporting%20Period) As of the reporting period end, the company had 57,007 shareholders, with China National Biotec Group as the largest shareholder and several state-owned entities among the top holders - As of the end of the reporting period, the total number of common shareholders was **57,007**[9](index=9&type=chunk) Top Three Shareholders' Holdings | Shareholder Name | Shares Held at Period End | Proportion (%) | | :--- | :--- | :--- | | China National Biotec Group Co., Ltd. | 626,736,450 | 49.96 | | Chengdu Institute of Biological Products Co., Ltd. | 48,484,330 | 3.87 | | Bank of China Co., Ltd. - E Fund Small and Mid-Cap Mixed Securities Investment Fund | 34,000,116 | 2.71 | - Chengdu Institute of Biological Products Co., Ltd. and Beijing Institute of Biological Products Co., Ltd. are subsidiaries of the largest shareholder, China National Biotec Group Co., Ltd., and are considered parties acting in concert[10](index=10&type=chunk) [Significant Events](index=7&type=section&id=Item%20III.%20Significant%20Events) Details major changes in financial statement items and indicators, including asset, liability, and profit variations, along with their underlying causes [Analysis of Significant Changes in Key Financial Statement Items and Indicators](index=7&type=section&id=3.1%20Analysis%20of%20Significant%20Changes%20in%20Key%20Financial%20Statement%20Items%20and%20Indicators%20and%20Their%20Causes) During the reporting period, several financial statement items experienced significant changes, driven by increased loans, project construction, R&D investment, and non-operating income [Balance Sheet Item Variation Analysis](index=7&type=section&id=Balance%20Sheet%20Related%20Data%20Significant%20Variation%20and%20Causes%20Table) Significant balance sheet changes include a 55.75% increase in monetary funds due to loans and sales, a 36.31% rise in construction in progress, and an 819.17% increase in accrued employee compensation Major Balance Sheet Item Changes | Statement Item | Period-End Balance (Yuan) | Growth Rate from Year-Start (%) | Primary Reason | | :--- | :--- | :--- | :--- | | Monetary Funds | 2,201,344,622.68 | 55.75% | Increased loans and sales collections | | Construction in Progress | 1,008,647,648.39 | 36.31% | Increased construction for Yong'an Blood Products and Yunnan projects | | Development Expenditures | 107,861,673.42 | 186.52% | Increased capitalized R&D project investment | | Short-term Borrowings | 200,113,888.89 | Not applicable | New 200 million Yuan special re-loan for epidemic | | Employee Compensation Payable | 197,673,049.64 | 819.17% | Increased accrual for employee compensation | [Income Statement Item Variation Analysis](index=8&type=section&id=Income%20Statement%20Related%20Data%20Significant%20Variation%20and%20Causes%20Table) Key income statement changes include a 730.41% increase in other income due to government subsidies and a 440.33% rise in investment income from equity fund returns Major Income Statement Item Changes (Year-to-Date) | Item | Amount (Yuan) | YoY Growth Rate (%) | Primary Reason | | :--- | :--- | :--- | :--- | | Other Income | 22,366,593.71 | 730.41% | Increased government subsidies | | Investment Income | 1,153,072.99 | 440.33% | Received returns from equity investment fund | | Non-operating Income | 2,291,253.51 | 692.54% | Increased donations, government subsidies, etc | [Cash Flow Statement Item Variation Analysis](index=8&type=section&id=Cash%20Flow%20Statement%20Related%20Data%20Significant%20Variation%20and%20Causes%20Table) Net cash flow from financing activities significantly increased by 216.08% due to a new 200 million Yuan special epidemic loan, contributing to a 101.38% rise in net cash and cash equivalents - Net cash flow from financing activities was **293 million Yuan**, a **216.08%** year-on-year increase, primarily due to obtaining a **200 million Yuan** special re-loan for the epidemic during the period[15](index=15&type=chunk) - Net increase in cash and cash equivalents was **788 million Yuan**, a **101.38%** year-on-year increase, mainly due to increased loans and sales collections[15](index=15&type=chunk) - Net cash paid for acquiring subsidiaries and other business units was **0**, compared to **22.89 million Yuan** in the prior year, leading to a decrease in cash outflow from investing activities[15](index=15&type=chunk) [Appendix](index=10&type=section&id=Item%20IV.%20Appendix) Contains the unaudited financial statements as of September 30, 2020, and details on the impact of new accounting standards [Financial Statements](index=10&type=section&id=4.1%20Financial%20Statements) The appendix provides unaudited financial statements as of September 30, 2020, including consolidated and parent company balance sheets, income statements, and cash flow statements - The appendix includes the company's unaudited consolidated balance sheet as of September 30, 2020[18](index=18&type=chunk) - The appendix includes the company's unaudited consolidated income statement for January-September 2020[25](index=25&type=chunk) - The appendix includes the company's unaudited consolidated cash flow statement for January-September 2020[34](index=34&type=chunk) [Explanation of Accounting Standard Changes](index=24&type=section&id=4.2%20Adjustments%20to%20Financial%20Statements%20at%20the%20Beginning%20of%20the%20First%20Year%20of%20Adoption%20of%20New%20Revenue%20and%20Lease%20Standards%20Starting%20from%202020) The company adopted new revenue standards from January 1, 2020, adjusting opening retained earnings and related financial statement items without retrospective restatement of prior period comparatives - The company adopted the new revenue standard from January 1, 2020, and in accordance with transitional provisions, did not adjust comparative period information, only adjusting relevant items at the beginning of the first year of adoption[44](index=44&type=chunk) Impact of New Revenue Standard Adoption on Opening Consolidated Balance Sheet | Item | Before Adjustment (2019-12-31) | After Adjustment (2020-01-01) | Adjustment Amount | | :--- | :--- | :--- | :--- | | Advances from Customers | 154,709,200.08 | 0 | -154,709,200.08 | | Contract Liabilities | 0 | 276,023,137.17 | 276,023,137.17 | | Other Payables | 347,604,481.65 | 218,009,850.45 | -129,594,631.20 | | Other Current Liabilities | 0 | 8,280,694.11 | 8,280,694.11 |